REG Iα is a biomarker for predicting response to chemotherapy with S-1 plus cisplatin in patients with unresectable stage IV gastric cancer.
Br J Cancer
; 108(2): 395-401, 2013 Feb 05.
Article
em En
| MEDLINE
| ID: mdl-23322208
ABSTRACT
BACKGROUND:
The regenerating gene Iα (REG Iα) is involved in gastric carcinogenesis as an antiapoptotic factor. Therefore, we investigated whether REG Iα confers resistance to chemotherapeutic drugs in gastric cancer (GC) cells and whether REG Iα expression is useful for predicting the response to chemotherapy and outcome in patients with GC.METHODS:
A total of 70 patients with unresectable stage IV GC received first-line chemotherapy with S-1 and cisplatin (S-1/CDDP). The expression of REG Iα was evaluated immunohistochemically using biopsy samples obtained before chemotherapy, and its relationship to clinicopathological parameters was analysed statistically. The effects of REG Iα gene induction on resistance to 5-FU or CDDP treatment were examined by cell survival assay and flow cytometry.RESULTS:
Of the 70 patients with unresectable stage IV GC, 19 (27%) were positive for REG Iα expression. The expression of REG Iα was independently predictive of poorer progression-free and overall survival in such patients (hazard ratio (HR) 2.46; P=0.002 and HR 1.89; P=0.037, respectively). The gene induction of REG Iα conferred resistance to cell death induced by 5-FU or CDDP in GC cells.CONCLUSION:
In patients with stage IV GC, REG Iα, which confers resistance to chemotherapeutic drugs in GC cells, is a potential biomarker for predicting resistance to S-1/CDDP treatment.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Ácido Oxônico
/
Neoplasias Gástricas
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Tegafur
/
Cisplatino
/
Litostatina
/
Fluoruracila
Idioma:
En
Ano de publicação:
2013
Tipo de documento:
Article
País de afiliação:
Japão